While our ultimate goal is to introduce the engineered bacteria directly into human patients, the next key decision point, and the focus of our PHRT project, involves extensive characterization of the technology in human patient samples cultured in the laboratory. The use of human sample cultures allows us to characterize the technology in a clinical context, which will be a critical element in meeting the extensive regulatory requirements required to deploy the system directly in patients. Towards accomplishing these objectives, we will specifically establish the human sample culture system and characterize our living diagnostic technology in multiple clinical contexts.